Last reviewed · How we verify
Ginkgo Biloba Extract 761
At a glance
| Generic name | Ginkgo Biloba Extract 761 |
|---|---|
| Also known as | Ginkgo biloba also named Egb761 or Ginaton |
| Sponsor | Dongzhimen Hospital, Beijing |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI (PHASE2)
- Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis (PHASE3)
- Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
- Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia (PHASE2)
- EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
- A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints (PHASE4)
- A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke (PHASE3)
- Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginkgo Biloba Extract 761 CI brief — competitive landscape report
- Ginkgo Biloba Extract 761 updates RSS · CI watch RSS
- Dongzhimen Hospital, Beijing portfolio CI